Besides providing an objective and clinically implementable means to grade IDH-mutant astrocytomas, our study is unique in that we used a prospectively collected sample cohort (CATNON), performed integrated analysis on three independent datasets, used treatment-naïve samples for signature development and included single-nucleus RNAseq data. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).